Member Info for Vander

This is all a bit odd- there are some on here who believe that fowler will roar back in a blaze of glory on a steed with kishani on the back- or maybe the strategic investor- the share price will go ‘nuts’ it was said- it’s all quite exciting

Fowler has explained the suspension is due to time constraints- it’s ok a clerical error- no need to worry

Fowler has achieved a deep state of suspended animation, a perfect reverie

At some point he need up to come up with some excuses for the aim suspension; maybe no one will notice if he keeps quiet, flick a switch, it was all a dream

These are all useful reflections; the Ecowas meeting was in dec 24 and presumably was well signposted for planned implementation from 01/01/26. Fowler has not mentioned these concerns to date and will dismiss or hide them unless forced to

Here is the link to official docs and there other useful articles online. He Ecowas policy will influence the ongoing Gabon negotiations regarding the n7/wsg security fee

https://www.ecowas.int/wp-content/uploads/2025/12/RELATING-TO-THE-COMMON-POLICY-ON-AVIATION-CHARGES-TAXES-AND-FEES-IN-ECOWAS-MEMBRE-STATE-1.pdf

Https://www.engagesalone.org/business-economy/ecowas-cuts-air-travel-taxes-will-sierra-leone-see-relief/

From 1 January 2026, all ECOWAS Member States will remove taxes applied to air transport and reduce passenger and security charges by 25 percent,” the regional bloc says in an article on its website.

It’s not yet happened at lungi I notice- 25usd still charged

In March 2018 Beaufort was the joint broker for WSG

Fowler is attracted like a flame to these types

Fowler’s two areas of strength are:

- RNS with plausible deniability with long timelines which burn off the majority of disgruntled investors

-Also he has been fantastic at metronomic placings

The advent of pantheon is blocking his style- making it impossible for him to work

There was a noticeable change in tone in the RNS

Lack of the usual bull.

Fowler is better writing RNS than in person and he is mediocre and uninspiring at public speaking. The RNS however are usually cushioned with positive assurances about future contracts and revenue- although history confirms these are fragile promises to dupe the gullible. Fowler is an experienced operator who mugs newbies

Yesterdays RNS lacked detail with very little explanation for the delay in accounts and was too vague (even for fowler) regarding the strategic multi-continent investor and recycled project finance initiative

I wonder if fowler is ok?

Fowler has previously boasted of rewarding loyal investors with a Xmas present eg the ‘middle east’ contract

I see the delayed accounts as a variation on this- it’s quite exciting to see what they reveal- although fowler is good at hide and seek, with the nomad giving up prematurely

I was hoping it was David Alastair smith of Avacta- shame about the middle name

Https://www.mdanderson.org/newsroom/research-newsroom/ash-2025--car-t-cell-therapy-shows-promising-phase-ii-trial-results-in-multiple-myeloma.h00-159781968.html

Kelonia therapeutics (Australia) were accepted

Only 3 patients phase one- all mrd at one month and P1 showed disability at 3 months

In vivo CAR T cell for r/r myeloma- no prior lymphodepletion and extraneous manufacture

Strategic collaboration with J&J on 5/11 ie collaboration then conference

The other late breaking oral presentations were mainly phase 3 results

Has hemo submitted a poster abstract?

More detailed account of court judgement

https://www.legalfutures.co.uk/latest-news/lawyer-sexually-harassed-female-colleague-54-years-his-junior

The median survival for r/r aml patients eligible and receiving intensive therapy is 13.6 months

Also a secondary outcome of the trial is CR ? (rather than MRD, necessitating flow cytometry

A key concern is safety and rate of CRS etc- doing well here so far at lowest dose- although depends alot on the patient characteristics eg leukaemia cell burden, age

Also a key problem for CAR T cell in r/r AML which has blocked progress despite good CR rates, is the durability of response- hence see strategies for optimisation in ASH 2024 summary publication (march 25) and nature review June 25

Gabon imposes Africa’s highest international air travel tax at $297.70, followed closely by Sierra Leone at $294 and Nigeria at $180.

Libya charges the lowest air travel tax among the listed African countries at just $1.30, with other low-cost countries including Malawi ($5.00), Lesotho ($5.70), and Algeria ($9.80).

The science is super and the aim laudable

They are broadening the range of antigens tested

However it will have to be a bullseye to progress smoothly- otherwise they don’t have to capacity to optimise it

The funding is piecemeal, dependent on the foreseeable risk profile- meaning progress is stop/start

Why else did they start the trial and then announce change of manufacturer after 2 patients? Especially given how complex and integral the process is

Am J Blood Res. 2020 Aug 25;10(4):124–133

In a 2020 population based study of outcomes in 199 r/r aml patients

The unadjusted median overall survival (OS) of the study cohort was 5.3 months from the time of RR-AML diagnosis, with a 5-year OS rate of 12.6% (95% confidence interval 7.5-21.1). According to treatment intensity after RR-AML, the median OS outcomes were 13.6, 9.4, and 2.0 months for IT, NIT, and BSC groups, respectively (P

This won’t be presented at ASH 2025 imho-there are only 3 patients

Let’s see what happens

Humbug- my previous post on dose response did not copy and paste correctly

Essentially dose level 1 for hg ct 1 was 70 million cells- above that expected to show increased efficacy with higher doses, based in the below:

Within the studies that showed association between dose and ORR, the starting dose was comparatively lower (